This Week in Nature

In Nature this week, a team led by researchers at St. Jude Children's Research Hospital report a novel therapy for retinoblastoma. The team performed genomic and epigenetic analyses of retinoblastoma samples, and found that the cancer's genome is stable, though several of its pathways can be deregulated. As the team reports, the only known cancer gene mutated in these tumors is RB1, and that the overall mutational rate is very low.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Alnylam's RNAi-based therapy Onpattro, according to Stat News.

Harvard Medical School's Seth Cassel and Cigall Kadoch argue in a Baltimore Sun op-ed that the recent TAILORx trial shows the potential of genomic-based medicine.

Researchers in the UK are working on using gene drives to control malaria-carrying mosquitoes, the Telegraph reports.

In PLOS this week: genetic architecture mediating gene expression, metabolomic patterns in multiple myeloma, and more.